ReviewFrontiers in physiology2020
Pathological Mechanisms in Diabetes of the Exocrine Pancreas: What's Known and What's to Know.
Review in Frontiers in physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Declining incidence of hypoglycaemia in diabetes secondary to chronic pancreatitis: A nationwide cohort study from 2003 to 2022.Diabetes, obesity & metabolism · 2025Article
- Unravelling the heterogeneity of diabetes in chronic pancreatitis: Alpha and beta cell dysfunction and association with glycaemic control.Diabetic medicine : a journal of the British Diabetic Association · 2025Article
- Increased Glycemic Variability in Patients With Chronic Pancreatitis and Diabetes Compared to Type 2 Diabetes.Journal of diabetes science and technology · 2025Article
- Exploring cutting-edge approaches in diabetes care: from nanotechnology to personalized therapeutics.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Protective Effects of Chitosan-Loaded Pomegranate Peel Extract Nanoparticles on Infertility in Diabetic Male Rats.Current topics in medicinal chemistry · 2025Article
- Using GeoMx DSP Spatial Proteomics to Investigate Immune Infiltration of NOD Mouse Islet and Exocrine Compartments.Molecular imaging and biology · 2024Article
- Mechanism exploration and biomarker identification of glycemic deterioration in patients with diseases of the exocrine pancreas.Scientific reports · 2024Article
- Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2024Article
- A novel clinical model for risk prediction and stratification of new-onset diabetes mellitus after distal pancreatectomy.Hepatobiliary surgery and nutrition · 2023Article
- Regional differences in islet amyloid deposition in the residual pancreas with new-onset diabetes secondary to pancreatic ductal adenocarcinoma.World journal of gastrointestinal surgery · 2023Article
- Article
- Optimal glycated hemoglobin A1c value for prediabetes and diabetes in patients with pancreatic diseases.Frontiers in endocrinology · 2023Article
- Pancreas Imaging of Children with Type 1 Diabetes Reveals New Patterns and Correlations with Pancreatic Functions.Pediatric diabetes · 2023Article
- Arctostaphylos uva-ursi L. leaves extract and its modified cysteine preparation for the management of insulin resistance: chemical analysis and bioactivity.Natural products and bioprospecting · 2022Article
- Diabetes mellitus: Plasticizers and nanomaterials acting as endocrine-disrupting chemicals (Review).Experimental and therapeutic medicine · 2022Review
- A Review on the Antidiabetic Properties ofFrontiers in pharmacology · 2022Review
- Pancreas-Its Functions, Disorders, and Physiological Impact on the Mammals' Organism.Frontiers in physiology · 2022Review
- Purinergic and Adenosinergic Signaling in Pancreatobiliary Diseases.Frontiers in physiology · 2022Review
- Crosstalk between adipose tissue and the microbiota-gut-brain axis in metabolic diseases.International journal of biological sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
The clinical significance of diabetes arising in the setting of pancreatic disease (also known as diabetes of the exocrine pancreas, DEP) has drawn more attention in recent years. However, significant improvements still need to be made in the recognition, diagnosis and treatment of the disorder, and in the knowledge of the pathological mechanisms. The clinical course of DEP is different from type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). DEP develops in patients with previous existing exocrine pancreatic disorders which damage both exocrine and endocrine parts of pancreas, and lead to pancreas exocrine insufficiency (PEI) and malnutrition. Therefore, damage in various exocrine and endocrine cell types participating in glucose metabolism regulation likely contribute to the development of DEP. Due to the limited amount of clinical and experimental studies, the pathological mechanism of DEP is poorly defined. In fact, it still not entirely clear whether DEP represents a distinct pathologic entity or is a form of T2DM arising when β cell failure is accelerated by pancreatic disease. In this review, we include findings from related studies in T1DM and T2DM to highlight potential pathological mechanisms involved in initiation and progression of DEP, and to provide directions for future research studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.